Annals of Hematology

, Volume 91, Issue 2, pp 223–233

Clinical features and outcomes of Hodgkin’s lymphoma in Korea: Consortium for Improving Survival of Lymphoma (CISL)

  • Young-Woong Won
  • Jung Hye Kwon
  • Soon Il Lee
  • Sung Yong Oh
  • Won Seog Kim
  • Seok Jin Kim
  • Jong-Ho Won
  • Kyoung Ha Kim
  • Seong Kyu Park
  • Jin Seok Kim
  • Cheolwon Suh
  • Dok Hyun Yoon
  • Joon Seong Park
  • Min Kyoung Kim
  • Hawk Kim
  • Hye Jin Kang
  • Yeung-Chul Mun
  • Jae-Yong Kwak
  • Hyo Jung Kim
  • Hyeon-Seok Eom
Original Article

DOI: 10.1007/s00277-011-1297-x

Cite this article as:
Won, Y., Kwon, J.H., Lee, S.I. et al. Ann Hematol (2012) 91: 223. doi:10.1007/s00277-011-1297-x

Abstract

Ethnic and regional differences in the epidemiology and pathological aspects of Hodgkin’s lymphoma (HL) between Western and Asian patients may be associated with differences in clinical features and prognosis. We retrospectively analyzed the clinical and histopathological characteristics, therapeutic outcomes, and prognostic factors of 539 HL patients treated at 16 centers in Korea. We found that the incidence of histological subtypes of HL in Korea was similar to that in Western and other Asian countries. However, the incidence peaked between 16 and 30 years of age, unlike the bimodal age distribution seen in Western countries. In patients with stage I–IIA non-bulky disease, the complete response (CR) rate was similar between combined modality therapy and chemotherapy alone (93% vs. 84%, P = 0.44), and there was no difference in relapse-free survival (RFS) and overall survival (OS). Patients with stage I–II disease plus unfavorable factors and those with advanced-stage disease treated with combination chemotherapy regimens had an overall CR rate of 77%, with no difference between doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) and non-ABVD regimens (77.2% vs. 76.8%, P = 0.95). Among those patients who achieved final CR, there was no significant difference in RFS or OS between those who achieved interim CR and PR. Only the presence of B symptoms was independently predictive of a shorter RFS. Age > 45 years, Eastern Cooperative Oncology Group 2–4, and B symptoms were independent risk factors for death. Although the incidence of HL was lower in Korea than in Western countries, the distribution of morphological subtypes, treatment outcomes, and patient prognosis were similar.

Keywords

Hodgkin’s lymphomaTreatmentOutcomePrognosis

Copyright information

© Springer-Verlag 2011

Authors and Affiliations

  • Young-Woong Won
    • 1
  • Jung Hye Kwon
    • 2
  • Soon Il Lee
    • 3
  • Sung Yong Oh
    • 4
  • Won Seog Kim
    • 5
  • Seok Jin Kim
    • 5
  • Jong-Ho Won
    • 6
  • Kyoung Ha Kim
    • 6
  • Seong Kyu Park
    • 7
  • Jin Seok Kim
    • 8
  • Cheolwon Suh
    • 9
  • Dok Hyun Yoon
    • 9
  • Joon Seong Park
    • 10
  • Min Kyoung Kim
    • 11
  • Hawk Kim
    • 12
  • Hye Jin Kang
    • 13
  • Yeung-Chul Mun
    • 14
  • Jae-Yong Kwak
    • 15
  • Hyo Jung Kim
    • 16
  • Hyeon-Seok Eom
    • 1
  1. 1.Hematology–Oncology Clinic, Research Institute and HospitalNational Cancer CenterGoyang-siRepublic of Korea
  2. 2.Division of Hematology–Oncology, Department of Internal Medicine, Kangdong Sacred Heart HospitalHallym UniversitySeoulRepublic of Korea
  3. 3.Division of Hematology–Oncology, Department of Medicine, Dankook University HospitalDankook UniversityCheonanRepublic of Korea
  4. 4.Department of Internal Medicine, Dong-A University Medical CenterDong-A UniversityBusanRepublic of Korea
  5. 5.Division of Hematology–Oncology, Department of Medicine, Samsung Medical CenterSungkyunkwan UniversitySeoulRepublic of Korea
  6. 6.Division of Hematology–Oncology, Department of Internal Medicine, Soonchunhyang University HospitalSoonchunhyang UniversitySeoulRepublic of Korea
  7. 7.Department of Hematology–Oncology, Soonchunhyang University Bucheon HospitalSoonchunhyang UniversityBucheonRepublic of Korea
  8. 8.Department of Internal Medicine, Severance HospitalYonsei UniversitySeoulRepublic of Korea
  9. 9.Department of Oncology, Asan Medical CenterUniversity of Ulsan College of MedicineSeoulRepublic of Korea
  10. 10.Department of Hematology–Oncology, Ajou University HospitalAjou UniversitySuwonRepublic of Korea
  11. 11.Department of Internal Medicine, Yeungnam University Medical CenterYeungnam UniversityDaeguRepublic of Korea
  12. 12.Division of Hematology–Oncology, Ulsan University HospitalUniversity of UlsanUlsanRepublic of Korea
  13. 13.Division of Hematology/Oncology, Department of Internal Medicine, Korea Cancer Center HospitalKorea Institute of Radiological & Medical SciencesSeoulRepublic of Korea
  14. 14.Division of Hematology–Oncology, Ewha Womans University Mokdong HospitalEwha Womans UniversitySeoulRepublic of Korea
  15. 15.Division of Hematology–Oncology, Department of Internal Medicine, Chonbuk National University HospitalChonbuk National UniversityJeonjuRepublic of Korea
  16. 16.Department of Internal Medicine, Hallym University Sacred Heart HospitalHallym UniversityAnyangRepublic of Korea